Nav: Home

Researchers discovered new information on the regulation of cancer cell motility

August 19, 2020

PIM kinases are enzymes that promote metastatic growth and spread of cancer cells. Researchers from the University of Turku, Finland, have obtained new information on how the PIM kinases enhance cancer cell motility by regulating the formation of actin fibres in the cytoskeleton. The published results support the development of PIM-targeted therapies to prevent metastasis formation in cancer patients.

It is critical for the survival of cancer patients, whether the cancer cells remain in their primary location or start migrating around the body to form metastases into bones and other vital organs. In order to be able to prevent metastasis formation, more information is needed about the factors regulating cancer cell motility.

- We had previously observed that PIM kinases promote and PIM-inhibitory compounds reduce migration of prostate cancer cells, but now we found a new mechanism to explain these observations, says the leader of the research group, Dr. Päivi Koskinen from the Department of Biology at the University of Turku.

Cellular movements are motorised by cytoskeletal actin fibres which are constantly polymerised or depolymerised, unless they are capped by proteins that protect the ends of the fibres.

- We demonstrated that via phosphorylation, PIM kinases modify actin capping proteins so that they cannot bind to actin polymers. As a consequence, actin processing as well as cell motility are enhanced, describes PhD Niina Santio who had the main responsibility for the experimental research.

- By contrast, in the presence of PIM inhibitors, cells stuck to each other and did not move much.

Video Abstract Visualises the Results

The results published in the Cell Communication and Signaling journal help to better understand the pro-metastatic effects of both the PIM kinases and the anti-metastatic PIM inhibitors.

In addition to written and graphic abstracts, the research group also used a video abstract for the first time to present their data.

- A visual abstract is a nice way to summarise the main message of the research into a single figure. Now, we also had the opportunity to wrap up our results into a short informative video which was finalised by an expert team provided by the journal, explains Päivi Koskinen.
-end-
The video abstract: https://youtu.be/iLwiV1GRXJY

University of Turku

Related Cancer Cells Articles:

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.
Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.
Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.
Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.
Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.
New liver cancer research targets non-cancer cells to blunt tumor growth
'Senotherapy,' a treatment that uses small molecule drugs to target ''senescent'' cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, PhD, a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.
Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.
Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.
First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.
Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.
More Cancer Cells News and Cancer Cells Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.